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Due to non-affordability of GnRH analogues (GnRHa),
Medroxy Progesterone Acetate (MPA) is still used as a
treatment option in girls with CPP in India. The aim
here is to study the clinical features of girls with CPP in
respect to the age at presentation, etiology and outcome
as per the medication used for their treatment (GnRHa
vs MPA).
Retrospective study of 38 girls with CPP(19 idiopathic)
treated with either MPA or GnRHa (Luprorelin or Trip-
torelin) were followed up for period varying from 1 to
8 years. The progression of growth parameters in rela-
tion to their age, etiology and medication used for the
treatment was studied. Statistical analysis was done
using one way ANOVA, unpaired t-test and Pearson
correlation tests.
Mean age at onset of puberty in girls with idiopathic
ICPP(n=19), neurogenic NCPP(n=12) and hypothalamic
hamartoma(HH)(n=7) were 4.68±2.83, 5.32±2.20 and
1.76±1.44 years, respectively(P 0.003). Mean height sds
at presentation of all girls was higher (0.51±1.80) with
comparison to MPH sds (0.90±1.19)(P=0.0021). 70% of
the girls presented with SMR stage 3. Bone age was
more advanced as compared to height age in all
(P=0.0001) and this trend continued till last follow up.
At presentation, girls with ICPP were significantly hea-
vier and taller as compared to NCPP and HH (P=0.002
for weight SDS and 0.022 for height SDS). Mean base-
line LH, FSH and estradiol were 3.05±2.49 mIU/ml,
4.75±2.29 mIU/ml and 29.43 pg/ml; respectively. At pre-
sentation, bone age was more advanced in HH(BA/CA
P=0.0001 with BA/HA P=0.03) and LH levels signifi-
cantly higher(5.6±2.26; P=0.02). At last follow up, there
was no significant difference in weight sds(p=0.285),
height sds(p=0.074) and PAH sds(p=0.056) in girls of
different age groups and etiologies. After 4 years of
follow up, height sds was better with GnRHa(1.80±0.98)
as compared to MPA(P=0.01) but height sds with MPA
was also good(0.49±0.81).
Due to prevalence of CNS infections, the proportion
of NCPP(31.57%) is higher in our set up, as compared
to industrialized countries. With financial constraints,
MPA can be considered as a treatment option for CPP.
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